Armata Pharmaceuticals, Inc. (NYSE: ARMP) reported Q3 EPS of ($0.86), $0.60 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $950 thousand.

For earnings history and earnings-related data on Armata Pharmaceuticals, Inc. (ARMP) click here.